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ABSTRACT
We used the fluorescence ubiquitination-based cell cycle indicator (FUCCI) to 
monitor cell cycle arrest after treatment of FUCCI-expressing HeLa cells (FUCCI-HeLa) 
with a traditional Chinese medicine (TCM) herbal mixture LQ, previously shown to 
have anti-tumor and anti-metastatic activity in mouse models. Paclitaxel was used as 
the positive control. In 2D monolayer culture, the untreated control had approximately 
45% of the cells in S/G2/M phase. In contrast, the LQ-treated cells (9 mg/ml) were 
mostly in the G0/G1 (>90%) after 72 hours. After treatment with paclitaxel (0.01 μm), 
for 72 hours, 95% of the cells were in S/G2/M. In 2.5D Matrigel® culture, the colonies 
in the untreated control group had 40% of the cells in S/G2/M. LQ arrested the cells in 
G0/G1 after 72 hours. Paclitaxel arrested almost all the cells in S/G2/M after 72 hours. 
In 3D Gelfoam® culture, the untreated control culture had approximately 45% of cells 
in G2/M. In contrast, the LQ-treated cells were mostly in G0/G1 phase (>80%) after 
72 hours treatment. Paclitaxel resulted in 90% of the cells arrested in S/G2/M after 
72 hours. The present report suggests the non-toxic LQ has potential to maintain 
cancers in a quiescent state for long periods of time.
 INTRODUCTION
Traditional Chinese medicine (TCM) compositions 
usually comprise multiple herbs and many components 
may be are necessary for efficacy. We previously compared 
the efficacy of the TCM herbal mixture LQ against lung 
cancer in mouse models with doxorubicin (DOX) and 
cyclophosphamide (CTX). LQ was effective against 
primary and metastatic lung cancer without weight loss and 
organ toxicity. In contrast, although CTX and DOX had 
efficacy in the lung cancer models, they caused significant 
weight loss and organ toxicity. LQ also had anti-angiogenic 
activity as observed in lung tumors growing in nestin-driven 
green fluorescent protein (ND-GFP) transgenic nude mice, 
which selectively express GFP in nascent blood vessels. LQ 
also increased survival of tumor-bearing mice, comparable 
to DOX. In vitro, lung cancer cells were killed by LQ, 
comparable to cisplatinum. LQ selectively killed cancer cell 
lines compared to normal cell strains unlike cytotoxic drugs 
which killed both similarly [1].
In another previous study, LQ significantly 
inhibited pancreatic cancer tumor growth and metastasis 
in orthotopic models with no overt toxicity. LQ also 
increased survival of tumor‐bearing mice. The antitumor 
efficacy of LQ was comparable with gemcitabine (GEM), 
but with less toxicity than GEM [2].
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Sakaue-Sawano et al. [3] developed a fluorescence 
ubiquitination-based cell-cycle indicator (FUCCI). 
With FUCCI, G0/G1 cells express an orange-red 
fluorescent protein and S/G
2
/M cells express a yellow-
green fluorescent protein. We previously determined 
with FUCCI imaging the cell-cycle phase of invading 
cancer cells [4] and the spatial-temporal cell-cycle phase 
distribution of cancer cells within tumors before and after 
chemotherapy [5].
The present report uses FUCCI imaging to demon-
strate the effect of LQ on the cell cycle arrest of HeLa cells.
RESULTS AND DISCUSSION
Effect of LQ or paclitaxel on the cell-cycle phase 
distribution of FUCCI-HeLa cells growing in 
2D culture
Untreated control HeLa-FUCCI cells exhibited 
a combination of orange-red and yellow-green nuclei. 
Approximately 60% of the cells were in S/G
2
/M and 
40% in G0/G1. The cultures were approaching confluence. 
After treatment with LQ (9 mg/ml) for 72 hours, the 
HeLa-FUCCI cells were almost all arrested in G0/G1. 
Only approximately 5% were in S/G
2
/M phases and the 
remainder in G0/G1. After treatment with paclitaxel (0.01 
μM), for 72 hours, approximately 5% of the cells were in 
G0/G1 with the rest of the cells arrested in S/G2/M. Almost 
all the paclitaxel-treated cells fluoresced yellow-green, in 
contrast to LQ-treated cells, which almost all fluoresced 
orange-red (Figure 1).
Effect of LQ or paclitaxel on the cell-cycle phase 
distribution of FUCCI-HeLa cells growing in 
2.5D Matrigel culture
The untreated control cells exhibited a combination 
of orange-red and yellow-green nuclei with the cells 
growing in colonies. Approximately 50% of the cells 
were in S/G
2
/M and 50% in G0/G1. LQ (9 mg/ml) had a 
similar effect in Matrigel as on plastic, with most of the 
cells arresting in G0/G1 and only 10% in S/G2/M after 72 
hours of treatment. Paclitaxel (0.01 μM) in 2.5 D Matrigel 
culture, as in 2D culture, arrested the cells almost all in 
S/G
2
/M after 72 hours treatment (Figure 2).
Effect of LQ or paclitaxel on the cell-cycle phase 
distribution of FUCCI-HeLa cells growing in 
Gelfoam® histoculture
Control cells in Gelfoam® histoculture exhibited 
a combination of orange-red and yellow-green nuclei. 
Approximately 60% of the cells were in S/G
2
/M with almost 
20% in M, a surprisingly large percentage. Treatment with 
LQ (9 mg/M) for 72 hours resulted in over 80% of the 
cells being arrested in G0/G1, similar to 2 D plastic culture 
and 2.5 D Matrigel culture. Paclitaxel (0.01 μM) resulted 
in 90% of the cells arrested in S/G
2
/M, as in 2D and 2.5D 
culture, after 72 hours treatment (Figure 3).
Methionine deprivation, either by nutritional means 
or recombinant methioninase (rMETase) treatment, 
selectively trapped cancer cells in S/G
2
 [6, 7]. Excess 
thymidine, or its analogs, arrested cancer cells in S-phase 
[8–10]. The calcium-channel blocker mibefradil arrested 
glioblastoma cells at the G
1
/S checkpoint [11]. Statins, 
such as Lovastatin, can arrest cancer cells in G0/G1 [12, 
13]. PDO332991, a pyridopyrimidine-selective inhibitor 
of cyclin-dependent kinases 4 and 6, induced early-G0/G1 
arrest in various cancer cell types, including melanoma and 
breast cancer in vitro, and in cancer xenograft models. RO-
3306, also a cyclin-dependent kinase inhibitor, reversibly 
arrested 95% of treated cells in G
2
 phase [14–17]. Since LQ 
has been shown to be non-toxic, it has potential to maintain 
cancers in a quiescent state for long periods of time.
Previously-developed concepts and strategies 
of highly-selective tumor targeting [18–29] can take 
advantage of cell-cycle imaging of cancer cells and G0/G1 
blockage by LQ, described in the present report.
MATERIALS AND METHODS
Cell line
FUCCI-expressing HeLa cells were grown in 
DMEM supplemented with 10% fetal bovine serum.
Establishment of HeLa cells stably transfected 
with FUCCI plasmids
Plasmids expressing mKO2-hCdt1 (yellow-
green fluorescent protein) and mAG-hGem (orange-red 
fluorescent protein) (Medical and Biological Laboratory, 
Nagoya, Japan) [3], were transfected into HeLa cells with 
Lipofectamine™ LTX (Invitrogen).
Two-dimensional monolayer culture
FUCCI-expressing HeLa cells were grown as 
monolayer in 35 mm dishes in DMEM supplemented with 
10% fetal bovine serum.
Matrigel (2.5 D culture)
Matrigel (100 μl/chamber well) was pipetted into the 
center of the well and then allowed to spread evenly for 
15–30 minutes at 37°C in order for the Matrigel to solidify. 
FUCCI-expressing HeLa cells (4 × 104) were grown for 
4 days in Matrigel and DMEM supplemented with 10% fetal 
bovine serum.
Gelfoam® (3D culture)
Sterilized Gelfoam® was cut and placed in wells. 
The Gelfoam® was hydrated in DMEM medium for 
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24 hours. A pellet of HeLa-FUCCI cells (106) in 20~30 μl 
DMEM supplemented with 10% fetal bovine serum, was 
gently placed on top of the Gelfoam®. Medium was added 
to the same height as the Gelfoam®.
Preparation of crude extracts of chinese herbs
LQ consists of a mixture of the following Chinese 
medicinal herbs: Sinapis alba, Atractylodes macrocephala, 
Coix lacryma-jobi, and Polyporus adusta (School of 
Pharmacy, Nanjing University of Traditional Chinese 
Medicine, Nanjing, China) as previously reported [30]. 
The ratio of the herbs used was (2:3:4:3). Dried plant parts 
used were: Sinapis albe, seed; Atractylodes macrocephala, 
root; Coix lacryma-jobi, kernel; Polyporus adusta, whole 
mushroom. Each herb was extracted in boiling water for 
20 mins, the solution was filtered and the residue extracted 
with 75% ethanol when filtered. The water extract and 
ethanolic extract were combined and concentrated by 
lyophilization. The lyophilized powder was suspended in 
PBS and the mixture was vortexed for 1 min and incubated 
at 80°c for 30 min., cooled to room temperature, and was 
then centrifuged at 2000 rpm for 10 min. The supernatant 
was collected at a final concentration to 90 mg/ml and 
diluted and filtered through a 0.2 mm membrane for 
in vitro use [31].
Chemotherapy drugs
Paclitaxel (Taxol) (Bedford Laboratories, Bedford, 
OH) was prepared by diluting to 0.2 μM as a stock 
solution.
Figure 1: LQ or paclitaxel treatment of FUCCI-HeLa cells growing in 2D culture. G0/G1 arrest of HeLa FUCCI cells was 
observed with LQ (9 mg/ml) treatment. Untreated control cells were distributed throughout the cell cycle. Paclitaxel was used as the 
positive control and resulted in an S/G
2
/M block. Bar graphs show the distribution of the cell-cycle phases with each treatment or control. 
See Materials and Methods for details.
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Figure 2: LQ or paclitaxel treatment of FUCCI-HeLa cells growing in 2.5D Matrigel culture. G0/G1 arrest of HeLa-FUCCI 
cells was observed with LQ (9 mg/ml) treatment. Untreated control cells were distributed throughout the cell cycle. Paclitaxel was used as 
the positive control and resulted in an S/G
2
/M block. Bar graphs show the distribution of the cell-cycle phases. See Materials and Methods 
for details.
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Imaging of FUCCI-expressing HeLa cells
Confocal laser scanning microscopy was performed 
with the FV1000 confocal laser scanning microscope 
(Olympus Corp., Tokyo, Japan) with 2 laser diodes 
(473 nm and 559 nm). A 4× (0.20 numerical aperture 
immersion) objective lens and a 20× (0.95 numerical 
aperture immersion) objective lens (Olympus) were 
used. Scanning and image acquisition were controlled 
by Fluoview software (Olympus). The tracing data were 
imported to Velocity 6.0 version (Perkin Elmer), where all 
3D analysis was performed [32].
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Figure 3: LQ or paclitaxel treatment of FUCCI-HeLa cells growing in Gelfoam® histoculture. G0/G1 arrest of HeLa-FUCCI 
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